Skip redundant pieces
The Liver Center

Andrew Parkinson


A Parkinson

XenoTech LLC, Lenexa, Kansas, USA

Andrew Parkinson is founder and CEO of XenoTech LLC, a contract service org­an­iz­at­ion specializing in pre-clinical drug testing for pharm­aceutical comp­anies.  He is also adjunct professor of Pharmacology and Toxicology at the Univ­ersity of Kansas Medical Center.

Dr. Parkinson received a B.Sc. degree in medical biochemistry from the Univers­ity of Surrey, England, in 1977, and received a Ph.D. degree in biological chem­istry from the University of Guelph, Canada, in 1981.  After completing his post­doctoral training in drug metabolism at Hoffmann-La Roche, Dr. Parkinson joined the faculty at the University of Kansas Medical Center, where he was Professor of Pharmacology and Toxicology and Associate Director of the Center of Environ­mental and Occupational Health until June 30, 1999.  He founded XenoTech LLC in 1994.

Dr. Parkinson is a member of the editorial board of several scientific journals, and is an active member of several scientific societies.  He has served on NIH study section, and is a consultant to several pharmaceutical companies and the FDA. Dr. Parkinson’s res­earch focuses mainly on hepatic drug metabolism and toxicity, with a special emphasis on cyto­chrome P450 and human-based in vitro systems.

Summary


1977 Bachelor’s degree in Medical Biochemistry University of Surrey
England
1981 Ph.D. degree in Biological Chemistry University of Guelph
Canada
1981-1983 Post­doctoral training in drug metabolism  Hoffmann-La Roche
New Jersey
1983 - 1999 Professor of Pharmacology and Toxicology University of Kansas Medical Center
1994 Dr. Parkinson founded XenoTech LLC, a contract research organization specializing in pre-clinical drug testing for pharm­aceutical comp­anies.  


Andrew Parkinson now serves as the President and CEO of XenoTech, in addition to being an Adjunct Professor at the University of Kansas Medical Center.

His research interests focus mainly on hepatic drug metabolism and toxicity, with a special emphasis on cyto­chrome P450 and human-based in vitro systems.